Clinical TrialJun 8, 2026, 04:37 PM
DBV Technologies' VIASKIN Peanut Patch shows positive VITESSE data
AI Summary
DBV Technologies announced new positive data from its Phase 3 VITESSE study, demonstrating statistically significant efficacy of the VIASKIN Peanut Patch in children aged 4-7 years with peanut allergy and concomitant atopic conditions like asthma, other food allergies, or atopic dermatitis. The company also previewed the design of its recently initiated Phase 2 THRIVE study, which will evaluate the efficacy and safety of the VIASKIN Peanut Patch in achieving ad lib peanut consumption in infants aged 6-12 months. Both sets of findings will be presented at the EAACI Congress 2026.
Key Highlights
- VIASKIN Peanut Patch showed statistically significant efficacy vs. placebo in Phase 3 VITESSE study subgroups.
- Response rates for VIASKIN Peanut Patch vs. placebo: Asthma (48.3% vs. 19.6%), Food allergies (46.8% vs. 13.6%), Atopic dermatitis (47.2% vs. 13.2%).
- Overall responder rate in VITESSE study was 46.6% for VIASKIN Peanut Patch vs. 14.9% for placebo.
- Phase 2 THRIVE study initiated, enrolling approximately 250 infants aged 6-12 months with peanut allergy.
- THRIVE study will assess ad lib consumption of peanuts after three years of treatment.
- Data from VITESSE and THRIVE study design will be presented at EAACI Congress 2026 (June 12-15).
Price Impact
More from DBVT